Literature DB >> 23345599

Low-dose aspirin use and recurrent gout attacks.

Yuqing Zhang1, Tuhina Neogi, Clara Chen, Christine Chaisson, David J Hunter, Hyon Choi.   

Abstract

OBJECTIVE: To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients.
METHODS: We conducted an online case-crossover study of individuals with gout over 1 year. The following information was obtained during gout attacks: the onset dates, symptoms and signs, medications, and exposure to potential risk factors, including daily aspirin use and dosage, during the 2-day hazard period prior to the gout attacks. The same exposure information was also obtained over 2-day control periods.
RESULTS: Of the 724 participants analysed, 40.5% took aspirin ≤325 mg/day during either a hazard or a control period. Compared with no aspirin use, the adjusted OR of gout attacks increased by 81% (OR=1.81, 95% CI 1.30 to 2.51) for ≤325 mg/day of aspirin use on two consecutive days. The corresponding ORs were stronger with lower doses (eg, OR=1.91 for ≤100 mg, 95% CI 1.32 to 2.85). These associations persisted across subgroups by sex, age, body mass index categories and renal insufficiency status. Concomitant use of allopurinol nullified the detrimental effect of aspirin.
CONCLUSIONS: Our findings suggest that the use of low-dose aspirin on two consecutive days is associated with an increased risk of recurrent gout attacks. Recommended serum urate monitoring with concomitant use and dose adjustment of a urate-lowering therapy among patients with gout may be especially important to help avoid the risk of gout attacks associated with low-dose aspirin.

Entities:  

Keywords:  Epidemiology; Gout; Treatment

Mesh:

Substances:

Year:  2013        PMID: 23345599      PMCID: PMC3902644          DOI: 10.1136/annrheumdis-2012-202589

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.

Authors:  Alexander So; Marc De Meulemeester; Andrey Pikhlak; A Eftal Yücel; Dominik Richard; Valda Murphy; Udayasankar Arulmani; Peter Sallstig; Naomi Schlesinger
Journal:  Arthritis Rheum       Date:  2010-10

2.  Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

Authors:  T F YU; A B GUTMAN
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

3.  The case-crossover design: a method for studying transient effects on the risk of acute events.

Authors:  M Maclure
Journal:  Am J Epidemiol       Date:  1991-01-15       Impact factor: 4.897

4.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Authors:  John S Sundy; Herbert S B Baraf; Robert A Yood; N Lawrence Edwards; Sergio R Gutierrez-Urena; Edward L Treadwell; Janitzia Vázquez-Mellado; William B White; Peter E Lipsky; Zeb Horowitz; William Huang; Allan N Maroli; Royce W Waltrip; Steven A Hamburger; Michael A Becker
Journal:  JAMA       Date:  2011-08-17       Impact factor: 56.272

5.  Triggering of sudden death from cardiac causes by vigorous exertion.

Authors:  C M Albert; M A Mittleman; C U Chae; I M Lee; C H Hennekens; J E Manson
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

6.  Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis.

Authors:  M Harris; L R Bryant; P Danaher; J Alloway
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

Review 7.  Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.

Authors:  Tracy Wolff; Therese Miller; Stephen Ko
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

8.  Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators.

Authors:  M A Mittleman; M Maclure; G H Tofler; J B Sherwood; R J Goldberg; J E Muller
Journal:  N Engl J Med       Date:  1993-12-02       Impact factor: 91.245

Review 9.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

View more
  13 in total

Review 1.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

Review 2.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 3.  Management of gout in the primary care setting.

Authors:  Qin Jian Low; Tzyy Huei Lim; Shu Ann Hon; Qin Jia Low; Mak Woh Wei; Seng Wee Cheo; Azwarina Hanim Ramlan
Journal:  Malays Fam Physician       Date:  2022-02-20

4.  Relation of temperature and humidity to the risk of recurrent gout attacks.

Authors:  Tuhina Neogi; Clara Chen; Jingbo Niu; Christine Chaisson; David J Hunter; Hyon Choi; Yuqing Zhang
Journal:  Am J Epidemiol       Date:  2014-07-03       Impact factor: 4.897

Review 5.  [Hyperuricemia. When and how to treat?].

Authors:  M A Reuss-Borst
Journal:  Internist (Berl)       Date:  2016-02       Impact factor: 0.743

6.  Clinical characteristics of early- and late-onset gout: A cross-sectional observational study from a Chinese gout clinic.

Authors:  Bingqing Zhang; Weigang Fang; Xuejun Zeng; Yun Zhang; Ya Ma; Feng Sheng; Xinlei Zhang
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

7.  Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease.

Authors:  J W Zhang; W W Liu; Timothy A McCaffrey; X Q He; W Y Liang; X H Chen; X R Feng; Sidney W Fu; M L Liu
Journal:  Clin Interv Aging       Date:  2017-08-10       Impact factor: 4.458

Review 8.  Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options.

Authors:  Thomas Bardin; Pascal Richette
Journal:  BMC Med       Date:  2017-07-03       Impact factor: 8.775

Review 9.  Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.

Authors:  Romy Hansildaar; Daisy Vedder; Milad Baniaamam; Anne-Kathrin Tausche; Martijn Gerritsen; Michael T Nurmohamed
Journal:  Lancet Rheumatol       Date:  2020-09-01

10.  Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles-Results from a Population-Based PolSenior Study.

Authors:  Mateusz Winder; Aleksander J Owczarek; Małgorzata Mossakowska; Katarzyna Broczek; Tomasz Grodzicki; Łukasz Wierucki; Jerzy Chudek
Journal:  Int J Environ Res Public Health       Date:  2021-01-06       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.